Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — 121 Tech Investment Hong Kong (June 2019)
15 slides from Proteomics International Laboratories's conference presentation, Jun 13, 2019
Slide 1: Building a Global Diagnostics Business
For personal use only 121 Tech Investment Hong Kong 13th June 2019 BUILDING A GLOBAL ASX: PIQ DIAGNOSTICS BUSINESS
Slide 2: Disclaimer
DISCLAIMER For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to se
Slide 3: Corporate Overview
CORPORATE OVERVIEW For personal use only Proteomics International Laboratories Ltd (PIQ: ASX) is a medical CORPORATE SNAPSHOT – 11/06/2019 ASX code PIQ technology company at the forefront of predictive diagnostics and bioanalytical services Share Price $0.34 Shares on issue 80.5m PREDICTIVE DIAGNOST
Slide 4: Building a Global Diagnostics Business
BUILDING A GLOBAL DIAGNOSTICS BUSINESS For personal use only PromarkerD, a predictive test for diabetic kidney disease is being rolled out now. 425m ENORMOUS MARKET adults have diabetes globally. DE-RISKED CLINICALLY PromarkerD clinical studies completed successfully and validated by peer review. Li
Slide 5: A Major Opportunity
A MAJOR OPPORTUNITY For personal use only THE PROBLEM 425 million people have diabetes 1 in 3 diabetic adults currently have chronic kidney disease There are no early symptoms of diabetic kidney disease. Kidney function can fall below 15-20% with no symptoms. There is currently no available test for
Slide 6: PromarkerD Featured at the American Diabetes Association
PromarkerD FEATURED at the AMERICAN DIABETES ASSOCIATION For personal use only 6
Slide 7: Major Cost/Benefit Factor to Drive Uptake
MAJOR COST/BENEFIT FACTOR TO DRIVE UPTAKE For personal use only With PromarkerD Without PromarkerD Unequivocal Cost Benefit Test Price US$60 Dialysis cost US$72,000 per year Predicts kidney disease with 86% VS ongoing for the patient’s life accuracy up to four years out Unequivocal Patient Benefit N
Slide 8: Market Size?
50% Nth America & Caribbean MARKET SIZE? UNDIAGNOSED Africa Europe For personal use only South & Central America South-East Asia ➢ Hundreds of millions of Middle East & North Africa people could benefit from Western Pacific this test in terms of early Africa treatment to mitigate the Sth/Ctrl Americ
Slide 9: Market Breakdown - PromarkerD
MARKET BREAKDOWN - PromarkerDTM For personal use only MARKET SIZE TOTAL POTENTIAL REGION PARTNER (DIABETICS) OPPORTUNITY* Mexico Patia Biopharma 13m US$72m p.a. Spain Patia Europe 3.6m US$20m p.a. Dominican Republic Omics Global 1.1m US$6m p.a. TARGET MARKETS United States In Discussions 30m US$165m
Slide 10: Janssen Collaboration - CDx
JANSSEN COLLABORATION - CDx For personal use only Proteomics International and Janssen Research & Development (Janssen) have formed a collaboration, utilizing PromarkerD to help assess the effectiveness of canagliflozin (Janssen diabetes drug) as a treatment for diabetic kidney disease. POSITIVE PHA
Slide 11: Analytical Services
ANALYTICAL SERVICES For personal use only WORLD’S FIRST COMPANY TO RECEIVE ISO 17025 LABORATORY ACCREDITATION FOR PROTEOMICS SERVICES BIOSIMILARS & BIOLOGICS PHARMACOKINETIC TESTING Assisting pharmaceutical companies Pre-clinical and clinical quantitative develop generic drugs testing of any new inv
Slide 12: Proteomics Vs Typical Biotechs
PROTEOMICS Vs TYPICAL BIOTECHS For personal use only ALL THE UPSIDE WITHOUT THE CLINICAL RISKS, COSTS & EXTENDED TIMELINES Features PIQ Typical Biotechs Enormous markets ✓ ✓ Minimal clinical risk ✓ X No waiting for results ✓ X Short clinical development (for new products) ✓ X No binary outcome ✓ X L
Slide 13: Milestones & Upcoming Catalysts
MILESTONES & UPCOMING CATALYSTS For personal use only EXCEPTIONAL GLOBAL OPPORTUNITY SHARE PRICE CATALYSTS ✓ Proven diagnostics business with global potential PromarkerD ✓ Scalable licensing model with high margins and Further licencing deals in major territories negligible rollout cost Expansion of
Slide 14: Board & Management
BOARD & Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and MANAGEMENT non-executive capacities. Companies include XRFAfrica Scientific Ltd, where he was For personal use only South & Managing Director for 4 years, Western Biotechnology Ltd,
Slide 15: Contact
CONTACT For personal use only Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Adelaide Equity Partners E: r.lipscombe@proteomicsinternational.com T: +61 8 8232 8800 www.proteomicsinternational.com E: dvandissel@adelaideequity.com.au Alast
Proteomics International Laboratories — 121 Tech Investment Hong Kong (June 2019) on 6ix